You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Friday, June 2, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

       

       

      CME / ABIM MOC

      Case in Point: An Expert's Approach to Caring for Patients With Glioblastoma

      • Authors: David Reardon, MD
      • CME / ABIM MOC Released: 2/22/2023
      • Valid for credit through: 2/22/2024
      Start Activity

      • Credits Available

        Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

        ABIM Diplomates - maximum of 0.25 ABIM MOC points

        You Are Eligible For

        • Letter of Completion
        • ABIM MOC points

      Target Audience and Goal Statement

      This activity is intended for oncologists, including radiation oncologists, neurologists, surgeons, and other clinicians involved in the care of patients with glioblastoma (GBM).

      The goal of this activity is for learners to be better able to care for patients with GBM.

      Upon completion of this activity, participants will:

      • Have increased knowledge regarding the
        • Available treatment options for first-line management of GBM
      • Have greater competence related to
        • Personalizing care for patients with GBM
      • Demonstrate greater confidence in their ability to
        • Communicate treatment considerations with patients receiving therapy for GBM

      Disclosures

      Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

      All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

      Faculty

      • David Reardon, MD

        Professor of Medicine
        Harvard Medical School
        Clinical Director
        Center for Neuro-Oncology
        Dana-Farber Cancer Institute
        Boston, Massachusetts

        Disclosures

        David Reardon, MD, has the following relevant financial relationships: 
        Consultant or advisor for: AbbVie Inc.; Advantagene; Agenus; Agios Pharmaceuticals; Amgen, Inc.; AnHeart Therapeutics; Avita Biomedical, Inc.; Bayer HealthCare; Boston Biomedical Associates; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Celldex Therapeutics, Inc.; Dainippon Sumitono Pharma America; Deciphera Pharmaceuticals, Inc.; Del Mar Pharma; DNAtrix; Ellipses Pharma; EMD Serono, Inc.; F. Hoffman-LaRoche, Ltd; Genenta; Genentech/Roche; Imvax; Inovio; Janssen Research & Development, LLC; Johnson & Johnson; Kintara; Kiyatec; Medicenna Biopharma, Inc.; Merck & Co., Inc.; Merck KGaA; Monteris; Neuvogen; Novartis Pharmaceuticals; Novocure; Oncorus; OXiGENE, Inc.; Pyramid; Regeneron Pharmaceuticals, Inc.; Stemline; Taiho Oncology, Inc.; Vivacitas Oncology, Inc., Y-mabs Therapeutics
        Research funding from: Acerta Pharma; Agenus; Bristol Myers Squibb Company; Celldex Therapeutics, Inc.; EMD Serono, Inc.; Enterome; Epitopoietic Research Corporation; Incyte Corporation; Inovio; Insightec; Merck & Co., Inc.; Novartis Pharmaceuticals; Omniox; Tragara

      Editors

      • Charlotte Warren

        Senior Director, Content Development, Medscape, LLC 

        Disclosures

        Charlotte Warren, has no relevant financial relationships.

      • Hennah Patel, MPharm, RPh

        Medical Writer, Medscape, LLC 

        Disclosures

        Hennah Patel has no relevant financial relationships.

      Compliance Reviewer

      • Amanda Jett, PharmD, BCACP

        Associate Director, Accreditation and Compliance, Medscape, LLC

        Disclosures

        Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

      Peer Reviewer

      This activity has been peer reviewed and the reviewer has no relevant financial relationships.

      Accreditation Statements



      In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

        For Physicians

      • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

        Contact This Provider

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

      Follow these steps to earn CME/CE credit*:

      1. Read about the target audience, learning objectives, and author disclosures.
      2. Study the educational content online or print it out.
      3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

      *The credit that you receive is based on your user profile.

      From Medscape Education Oncology
      CME / ABIM MOC

      Case in Point: An Expert's Approach to Caring for Patients With Glioblastoma

      Authors: David Reardon, MDFaculty and Disclosures

      CME / ABIM MOC Released: 2/22/2023

      Valid for credit through: 2/22/2024

      processing....

      References

      1. American Association of Neurological Surgeons. Glioblastoma multiforme. Updated 2023. Accessed February 8, 2023. www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme
      2. Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231-1251.
      3. Kanderi T, et al. Glioblastoma multiforme. In: StatPearls. StatPearls Publishing; 2022. Updated September 12, 2022. Accessed February 16, 2023. https://www.ncbi.nlm.nih.gov/books/NBK558954/
      4. Tamimi AF, et al. Epidemiology and outcome of glioblastoma. In: De Vleeschouwer S, ed. Glioblastoma. Codon Publications; 2017.
      5. Miller KD, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381-406.
      6. Hakan T, et al. Glioblastoma shortly after a normal conventional brain magnetic resonance imaging: a report of two cases and review of the literature. Asian J Neurosurg. 2021;16:433-436.
      7. Hanif F, et al. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3-9.
      8. Osborn AG, et al. The 2021 World Health Organization Classification of Tumors of the Central Nervous System: what neuroradiologists need to know. AJNR Am J Neuroradiol. 2022;43:928-937.
      9. Alzial G, et al. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene. 2022;41:613-621.
      10. Han S, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580-1589.
      11. Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
      12. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Central nervous system cancers (Version 2.2022). September 29, 2022.
      13. Nayak L, et al. Primary brain tumors in the elderly. Curr Neurol Neurosci Rep. 2010;10:252-258.
      14. Abedi AA, et al. A prognostic model for glioblastoma patients treated with standard therapy based on a prospective cohort of consecutive non-selected patients from a single institution. Front Oncol. 2021;11:597587.
      15. Carr MT, et al. Comorbid medical conditions as predictors of overall survival in glioblastoma patients. Sci Rep. 2019;9:20018.
      16. Liu J, et al. Prognostic and predictive factors in elderly patients with glioblastoma: a single-center retrospective study. Front Aging Neurosci. 2022;13:777962.
      17. Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170-186.
      18. Salama GR, et al. Diffusion weighted/tensor imaging, functional MRI and perfusion weighted imaging in glioblastoma-foundations and future. Front Neurol. 2018;8:660.
      19. Luna LP, et al. Can preoperative mapping with functional MRI reduce morbidity in brain tumor resection? A systematic review and meta-analysis of 68 observational studies. Radiology. 2021;300:338-349.
      20. Mohile NA, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40:403-426.
      21. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
      22. Garcia CR, et al. Hematological adverse events in the management of glioblastoma. J Neurooncol. 2022;156:153-161.
      23. Temozolomide [prescribing information]. Approved 1999. Revised September 2015.
      24. Perry JR, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376:1027-1037.
      25. Roa W, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583-1588.
      26. Wick W, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707-715.
      27. Stupp R, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306-2316.
      28. Lacouture ME, et al. Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma. Front Oncol. 2020;10:1045.
      29. Lou E, et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2013;2:185-195.
      30. Bagley SJ, et al. Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin Cancer Res. 2022;28:594-602.
      « Return to: Case in Point: An Expert's Approach to Caring for Patients With Glioblastoma
      CME / ABIM MOC Information
      • Print
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.